Search Results - "MATSUGUMA, Kyoko"

Brivaracetam Single and Multiple Rising Oral Dose Study in Healthy Japanese Participants: Influence of CYP2C19 Genotype by Stockis, Armel, Watanabe, Shikiko, Rouits, Elisabeth, Matsuguma, Kyoko, Irie, Shin

“…Brivaracetam is a high-affinity synaptic vesicle protein 2A ligand, in phase 3 clinical development for epilepsy. A phase 1, single-center, randomized,…”
Get full text

Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease by MATSUMOTO, Yuriko, UEDA, Seiji, YAMAGISHI, Sho-Ichi, MATSUGUMA, Kyoko, SHIBATA, Ryo, FUKAMI, Kei, MATSUOKA, Hidehiro, IMAIZUMI, Tsutomu, OKUDA, Seiya

“…Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, is mainly degraded by dimethylarginine dimethylaminohydrolase (DDAH). It was…”
Get full text

Recapitulation of Clinical Individual Susceptibility to Drug-Induced QT Prolongation in Healthy Subjects Using iPSC-Derived Cardiomyocytes by Shinozawa, Tadahiro, Nakamura, Koki, Shoji, Masanobu, Morita, Maya, Kimura, Maya, Furukawa, Hatsue, Ueda, Hiroki, Shiramoto, Masanari, Matsuguma, Kyoko, Kaji, Yoshikazu, Ikushima, Ippei, Yono, Makoto, Liou, Shyh-Yuh, Nagai, Hirofumi, Nakanishi, Atsushi, Yamamoto, Keiji, Izumo, Seigo

“…To predict drug-induced serious adverse events (SAE) in clinical trials, a model using a panel of cells derived from human induced pluripotent stem cells…”
Get full text

Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease by MATSUGUMA, Kyoko, UEDA, Seiji, IMAIZUMI, Tsutomu, OKUDA, Seiya, YAMAGISHI, Sho-Ichi, MATSUMOTO, Yuriko, KANEYUKI, Utako, SHIBATA, Ryo, FUJIMURA, Toshiko, MATSUOKA, Hidehiro, KIMOTO, Masumi, KATO, Seiya

“…Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase. ADMA is generated by protein methyltransferase (PRMT) and is…”
Get full text

Mechanisms of Pharmacokinetic Enhancement Between Ritonavir and Saquinavir; Micro/Small Dosing Tests Using Midazolam (CYP3A4), Fexofenadine (p-Glycoprotein), and Pravastatin (OATP1B1) as Probe Drugs by Ieiri, Ichiro, Tsunemitsu, Shyohei, Maeda, Kazuya, Ando, Yukie, Izumi, Noritomo, Kimura, Miyuki, Yamane, Naoe, Okuzono, Tsuyoshi, Morishita, Mariko, Kotani, Naoki, Kanda, Eri, Deguchi, Mariko, Matsuguma, Kyoko, Matsuki, Shunji, Hirota, Takeshi, Irie, Shin, Kusuhara, Hiroyuki, Sugiyama, Yuichi

“…We investigated the mechanisms of ritonavir‐mediated enhancement effect on the pharmacokinetics of saquinavir using in vivo probes for CYP3A4 (midazolam),…”
Get full text

Pharmacokinetics and pharmacodynamics of FSK0808 and Gran after single intravenous drip administration or single subcutaneous administration: comparative study in healthy Japanese adult male subjects by Matsuguma, Kyoko, Matsuki, Shunji, Eunhee, Chung, Watanabe, Akimasa, Tanaka, Asuka, Sakamoto, Kei, Takeshita, Hiromi, Hitaka, Akiko, Shigetome, Kyoko, Kimura, Miyuki, Miyamoto, Akiko, Irie, Shin, Kaneko, Daiki, Ohnishi, Akihiro

“…Abstract FSK0808 is a recombinant human granulocyte colony-stimulating factor developed by Fuji Pharma Co., Ltd and Mochida Pharmaceutical Co., Ltd. as a…”
Get full text

Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPs and OATPs following oral microdosing by Ieiri, Ichiro, Fukae, Masato, Maeda, Kazuya, Ando, Yukie, Kimura, Miyuki, Hirota, Takeshi, Nakamura, Takeshi, Iwasaki, Kazuhide, Matsuki, Shunji, Matsuguma, Kyoko, Kanda, Eri, Deguchi, Mariko, Irie, Shin, Sugiyama, Yuichi

“…To test whether the multiple phenotype and genotype relationships established using therapeutic dose, can be reproduced following oral microdosing using…”
Get full text

A comparative pharmacokinetic and pharmacodynamic study of FSK0808 versus reference filgrastim after repeated subcutaneous administration in healthy Japanese men by Matsuguma, Kyoko, Matsuki, Shunji, Sakamoto, Kei, Shiramoto, Masanari, Nakagawa, Misato, Kimura, Miyuki, Irie, Shin, Kaneko, Daiki, Ohnishi, Akihiro

“…FSK0808, a biosimilar of filgrastim, is a recombinant human granulocyte colony‐stimulating factor developed by Fuji Pharmaceuticals and Mochida Pharmaceutical…”
Get full text

Pharmacokinetics and Pharmacodynamics of Landiolol Hydrochloride, an Ultra Short-acting β1-Selective Blocker, in a Dose Escalation Regimen in Healthy Male Volunteers by Murakami, Makoto, Furuie, Hidetoshi, Matsuguma, Kyoko, Wanibuchi, Atsuko, Kikawa, Shinichi, Irie, Shin

“…We conducted a randomized, double-blind, placebo-controlled study to evaluate the pharmacokinetics and pharmacodynamics of landiolol hydrochloride in a dose…”
Get full text

Pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra short-acting beta1-selective blocker, in a dose escalation regimen in healthy male volunteers by Murakami, Makoto, Furuie, Hidetoshi, Matsuguma, Kyoko, Wanibuchi, Atsuko, Kikawa, Shinichi, Irie, Shin

“…We conducted a randomized, double-blind, placebo-controlled study to evaluate the pharmacokinetics and pharmacodynamics of landiolol hydrochloride in a dose…”
Get full text

BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid A[beta] Peptides by Sakamoto, Kei, Matsuki, Shunji, Matsuguma, Kyoko, Yoshihara, Tatsuya, Uchida, Naoki, Azuma, Fumihiko, Russell, Muir, Hughes, Glen, Haeberlein, Samantha Budd, Alexander, Robert C, Eketjall, Susanna, Kugler, Alan R

“…Lanabecestat (AZD3293; LY3314814) is an orally active potent inhibitor of human [beta]-secretase 1 in clinical development for the treatment of Alzheimer…”
Get full text

BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides by Sakamoto, Kei, Matsuki, Shunji, Matsuguma, Kyoko, Yoshihara, Tatsuya, Uchida, Naoki, Azuma, Fumihiko, Russell, Muir, Hughes, Glen, Haeberlein, Samantha Budd, Alexander, Robert C., Eketjäll, Susanna, Kugler, Alan R.

“…Lanabecestat (AZD3293; LY3314814) is an orally active potent inhibitor of human β‐secretase 1 in clinical development for the treatment of Alzheimer disease…”
Get full text

Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study by Ohba, Fuminori, Matsuki, Shunji, Imayama, Shuhei, Matsuguma, Kyoko, Hojo, Seiichiro, Nomoto, Maiko, Akama, Hideto

“…Introduction: Phosphodiesterase type 4 (PDE4) inhibition is a well-known anti-inflammatory mechanism. However, the clinical use of PDE4 inhibitors has been…”
Get full text

Pharmacokinetic Bioequivalence, Safety, and Immunogenicity of DMB-3111, a Trastuzumab Biosimilar, and Trastuzumab in Healthy Japanese Adult Males: Results of a Randomized Trial by Morita, Jun, Tanaka, Masashi, Nomoto, Masahiro, Matsuki, Shunji, Tsuru, Tomomi, Matsuguma, Kyoko, Shiramoto, Masanari

“…Background DMB-3111 is a biosimilar trastuzumab drug being jointly developed by Meiji Seika Pharma (Japan) and Dong-A Socio Holdings (Korea). We investigated…”
Get full text

P2‐002: Assessment of The Safety, Tolerability, Pharmacokinetics, and Effects on Plasma and Cerebrospinal Fluid AB Peptides of AZD3293, a Novel Bace1 Inhibitor, in Healthy Japanese Adults by Yoshihara, Tatsuya, Sakamoto, Kei, Matsuki, Shunji, Matsuguma, Kyoko, Uchida, Naoki, Azuma, Fumihiko, Russell, Muir, Hughes, Glen, Haeberlein, Samantha Budd, Alexander, Robert C., Kugler, Alan R.

Get full text

ASSESSMENT OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFECTS ON PLASMA AND CEREBROSPINAL FLUID AB PEPTIDES OF AZD3293, A NOVEL BACE1 INHIBITOR, IN HEALTHY JAPANESE ADULTS by Yoshihara, Tatsuya, Sakamoto, Kei, Matsuki, Shunji, Matsuguma, Kyoko, Uchida, Naoki, Azuma, Fumihiko, Russell, Muir, Hughes, Glen, Haeberlein, Samantha Budd, Alexander, Robert C, Kugler, Alan R

Get full text